الفهرس 
INTRODUCTIONOnly 14 pages are availabe for public view
 |  | from | 137 |  |  |
| | | from | 137 | | |
Abstract
Bone ‘tumors’ are either benign or malignant. Benign tumors include both true neoplasm and tumor-like lesions. All malignant bone tumors are neoplastic, either primary or secondary. The pre-biopsy diagnosis of a bone tumor depends upon several features, including age of the patient, site of the lesion within the skeleton and the individual affected bone and finally the radiological characteristics. Improvement in the treatment and outcome of osseous bone tumors requires the development of diagnostic tool that can help to differentiate between benign and malignant lesion in a non invasive and reliable manner. Plain radiography should be obtained early in the work up of symptomatic patients because it is non expensive and provides the most specific informations regarding the true nature of the lesion .The radiographic finding and the degree of clinical suspicion dictate further work up. Multislice-CT (MS-CT) is the most frequently used imaging modality in osseous tumors in axial orientation with multi-planar reconstructions. It has many excellent advantages in improving imaging of osseous bone tumors such as increased temporal & spatial resolusion ,decrease image noise, increase scan speed & longer area of coverage. CT will give an impression of the predominant variety of tissue present. particularly if there is fat or calcification. Examines the intra osseous extent of the tumor, looking for subtle changes in medullary fat and examines also extra osseous extent and soft tissue relationships. CT detects more pulmonary metastasis than is possible with a conventional chest radiograph. Bone biopsy under C.T. control is now an essential maneuver in pathological diagnosis and before operative or chemotherapy treatment . Magnetic resonance imaging (MRI) has high soft tissue contrast. Its high spatial resolution has gained an important role in the detection, characterization, staging and follow-up of musculoskeletal tumors. Dynamic contrast enhanced MRI has been advocated for determining chemotherapeutic response.